The earnings call reflects strong operational and financial performance with record-breaking results and increased guidance. However, the disappointment from the blood-based test results and reliance on external technology for CRC blood screening pose challenges. Nonetheless, the expansion of Cologuard Plus and new product launches demonstrate robust growth potential.

Company Guidance -

Q3 2025

In the Exact Sciences second quarter 2025 earnings call, the company reported significant growth and updated guidance, highlighting several key metrics. Exact Sciences delivered a record 1.3 million test results, with core revenue growth accelerating to 16% year-over-year, leading to an all-time high of $138 million in adjusted EBITDA. Consequently, the company raised its revenue guidance midpoint by $55 million and adjusted EBITDA by $25 million. Screening revenue grew by 18% to $628 million, while precision oncology revenue increased by 9% to $179 million. The company also forecasted third-quarter revenue between $800 million and $815 million, and full-year total revenue between $3.13 billion and $3.17 billion, representing annual growth of 14%. Adjusted EBITDA guidance for the full year was increased to a range of $455 million to $475 million, implying a growth of over 44% and a margin expansion of about 300 basis points. Exact Sciences also announced a multiyear productivity plan targeting $150 million in annual savings by 2026, with $50 million of these savings reflected in the 2025 guidance.

Record Test Results and Revenue Growth

Exact Sciences delivered a record 1.3 million test results, with core revenue growth accelerating to 16% year-over-year. Adjusted EBITDA reached an all-time high of $138 million.

Increased Financial Guidance

Revenue guidance was raised by $55 million at midpoint, and adjusted EBITDA guidance was increased by $25 million.

Expansion of Cologuard Plus

The company expanded its agreement with two top payers, Humana and Centene, to include Cologuard Plus in-network, covering about 40 million members.

Medicare Coverage for Oncodetect

Gained Medicare reimbursement for Oncodetect, a molecular residual disease test, supporting its role in cancer treatment monitoring.

Launch of Cancerguard Test

Announced the launch of Cancerguard, a blood-based multi-cancer early detection test targeting a $25 billion addressable market.

Exact Sciences (EXAS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EXAS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	>-0.01 / -	-0.21	―	―	―
Aug 06, 2025	2025 (Q2)	-0.13 / -0.01	-0.09	88.89% (+0.08)
May 01, 2025	2025 (Q1)	-0.36 / -0.54	-0.6	10.00% (+0.06)
Feb 19, 2025	2024 (Q4)	-0.30 / -4.67	-0.27	-1629.63% (-4.40)
Nov 05, 2024	2024 (Q3)	-0.20 / -0.21	0	―
Jul 31, 2024	2024 (Q2)	-0.34 / -0.09	-0.45	80.00% (+0.36)
May 08, 2024	2024 (Q1)	-0.48 / -0.60	-0.42	-42.86% (-0.18)
Feb 21, 2024	2023 (Q4)	-0.44 / -0.27	-0.72	62.50% (+0.45)
Nov 01, 2023	2023 (Q3)	-0.47 / 0.00	-0.84	―
Aug 01, 2023	2023 (Q2)	-0.49 / -0.45	-0.94	52.13% (+0.49)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EXAS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$46.91	$43.16	-7.99%
May 01, 2025	$47.16	$51.55	+9.31%
Feb 19, 2025	$50.48	$49.51	-1.92%
Nov 05, 2024	$71.51	$54.72	-23.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exact Sciences Corp. (EXAS) report earnings?

Exact Sciences Corp. (EXAS) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).

What is Exact Sciences Corp. (EXAS) earnings time?

Exact Sciences Corp. (EXAS) earnings time is at Oct 29, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EXAS EPS forecast?

EXAS EPS forecast for the fiscal quarter 2025 (Q3) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing